GNPX net incomeQ2 2026-$4.45M
GNPX net income was -$4.45M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.67M a year earlier. For the full fiscal 2025 it was -$16.23M, compared with -$21.11M in fiscal 2024.
Genprex Inc. (GNPX) financials
For the twelve months ended Jun 30, 2026, Genprex Inc. reported -$16.50M of net income.
- Net income, TTM
- -$16.50M
- Cash
- $15.15M
- Market cap
- $1.9M
FY2016FY2024
FY2016FY2025
FY2016FY2022
GNPX revenue and earnings growth
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | $0 | $0 | - | $0 | $0 | $0 |
| Research and development | $9.43M | $10.54M | $17.62M | $11.51M | $8.97M | $7.30M | $1.97M | $971.4K | $289.9K | $354.9K |
| Selling, general and admin | $6.09M | $10.63M | $13.43M | $12.30M | $11.68M | $10.64M | $8.70M | $11.39M | $3.02M | $3.78M |
| Operating income | -$15.52M | -$21.17M | -$31.06M | -$23.83M | -$20.67M | -$17.96M | -$10.68M | -$12.36M | -$3.31M | -$4.13M |
| Interest expense | - | - | - | - | - | - | - | $38.0K | $1.9K | $0 |
| Income tax | $0 | $2.6K | $0 | $0 | - | - | - | - | - | - |
| Net income | -$16.23M | -$21.11M | -$30.86M | -$23.74M | -$20.66M | -$17.94M | -$10.65M | -$12.37M | -$3.31M | -$4.13M |
| EPS, basic | -$17.40 | -$266.89 | -$22.56 | -$19.80 | -$0.44 | -$0.51 | -$0.66 | -$0.90 | -$0.29 | -$0.38 |
| EPS, diluted | - | - | - | - | -$0.42 | -$0.51 | -$0.66 | -$0.90 | -$0.29 | -$0.38 |
| Diluted shares | - | - | - | - | 47.1M | 35.5M | 16.0M | 13.8M | 11.5M | 10.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.83M | $1.60M | $6.74M | $20.95M | $38.63M | $27.32M | $2.00M | $8.60M | $161.3K | $1.60M |
| Receivables | - | - | $0 | $34.9K | $0 | $127 | $655 | $9.3K | $8.8K | $8.2K |
| Current assets | $8.36M | $2.08M | $7.53M | $21.47M | $39.14M | $27.70M | $2.98M | $8.85M | $193.6K | $1.64M |
| Total assets | $10.16M | $4.12M | $10.67M | $25.09M | $42.86M | $31.37M | $3.53M | $9.27M | $1.26M | $1.91M |
| Current liabilities | $2.17M | $2.50M | $3.25M | $2.81M | $1.59M | $450.7K | $510.7K | $387.8K | $831.0K | $285.7K |
| Total liabilities | $2.20M | $2.50M | - | - | $1.59M | - | - | - | - | - |
| Shareholders' equity | $7.96M | $1.62M | $7.42M | $22.27M | $41.28M | $30.92M | $3.02M | $8.88M | $428.6K | $1.62M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.31M | -$17.92M | -$24.74M | -$17.62M | -$14.28M | -$13.94M | -$6.92M | -$6.85M | -$2.17M | -$1.25M |
| Capital expenditures | - | - | - | $0 | $31.7K | $17.6K | $33.4K | $22.4K | $5.9K | $5.0K |
| Free cash flow | - | - | - | -$17.62M | -$14.32M | -$13.95M | -$6.95M | -$6.87M | -$2.18M | -$1.25M |
| Investing cash flow | $0 | $774.6K | -$71.2K | -$59.7K | -$83.8K | -$2.34M | -$946.9K | -$103.3K | -$63.4K | -$89.5K |
| Financing cash flow | $21.54M | $12.01M | $10.59M | $6.4K | $25.68M | $41.59M | $1.27M | $15.39M | $794.0K | $2.71M |
| Stock-based compensation | - | $3.30M | $5.41M | $4.73M | $5.35M | $4.25M | $3.53M | $5.44M | $1.32M | $2.66M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -203.8% | -1303.0% | -416.1% | -106.6% | -50.1% | -58.0% | -352.4% | -139.3% | -773.3% | -254.3% |
| Return on assets | -159.7% | -511.9% | -289.2% | -94.6% | -48.2% | -57.2% | -301.5% | -133.5% | -263.1% | -216.3% |
| Current ratio | 3.84 | 0.83 | 2.31 | 7.64 | 24.69 | 61.47 | 5.83 | 22.81 | 0.23 | 5.74 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.68M | $2.75M | $2.20M | $2.19M | $2.50M | $2.54M | $2.84M | $2.76M | $1.67M | $3.27M | $3.71M | $4.62M |
| Selling, general and admin | $1.80M | $1.75M | $1.32M | $1.15M | $2.18M | $1.43M | $1.50M | $1.57M | $4.85M | $2.72M | $2.25M | $3.17M |
| Operating income | -$4.48M | -$4.49M | -$3.52M | -$3.35M | -$4.68M | -$3.97M | -$4.34M | -$4.32M | -$6.52M | -$6.00M | -$5.97M | -$7.79M |
| Net income | -$4.45M | -$4.46M | -$3.79M | -$3.80M | -$4.67M | -$3.96M | -$4.33M | -$4.32M | -$6.50M | -$5.97M | -$5.93M | -$7.75M |
| EPS, basic | -$9.40 | -$0.64 | - | -$5.00 | -$185.30 | -$12.98 | - | -$61.65 | -$3.00 | -$3.86 | - | -$5.36 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.15M | $18.05M | $7.83M | $1.10M | $1.35M | $3.47M | $1.60M | $1.49M | $2.46M | $8.22M | $6.74M | $11.71M |
| Receivables | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 |
| Current assets | $15.84M | $18.80M | $8.36M | $1.72M | $2.06M | $4.16M | $2.08M | $1.92M | $4.39M | $9.23M | $7.53M | $12.86M |
| Total assets | $17.14M | $20.31M | $10.16M | $3.56M | $3.83M | $6.01M | $4.12M | $3.91M | $6.60M | $12.56M | $10.67M | $16.64M |
| Current liabilities | $2.34M | $3.35M | $2.17M | $2.55M | $2.44M | $2.14M | $2.50M | $2.24M | $2.26M | $3.81M | $3.25M | $4.34M |
| Total liabilities | $2.34M | $3.38M | $2.20M | $2.79M | - | - | $2.50M | - | - | - | - | - |
| Shareholders' equity | $14.80M | $16.93M | $7.96M | $767.8K | $1.39M | $3.87M | $1.62M | $1.66M | $4.35M | $8.76M | $7.42M | $12.31M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.14M | -$3.14M | -$4.10M | -$3.19M | -$3.86M | -$4.16M | -$3.87M | -$2.19M | -$6.57M | -$5.30M | -$4.96M | -$4.74M |
| Investing cash flow | - | - | $0 | $0 | $0 | $0 | -$1 | $0 | $790.5K | -$15.8K | -$9.8K | -$21.8K |
| Financing cash flow | $2.24M | $13.36M | $10.83M | $2.94M | $1.74M | $6.03M | $3.98M | $1.22M | $20.8K | $6.79M | $4 | $6.51M |
| Stock-based compensation | - | - | - | - | - | $184.2K | $302.8K | $420.2K | $2.06M | $516.0K | $1.04M | $1.49M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.77 | 5.61 | 3.84 | 0.67 | 0.84 | 1.94 | 0.83 | 0.86 | 1.95 | 2.42 | 2.31 | 2.96 |
Source: XBRL data Genprex Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GNPX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GNPX | - | - | -$16.50M | - | $1.9M |
| KRYS | $470.02M | +26.0% | $225.17M | 47.9% | $9.15B |
| RCKT | $0 | - | -$17.25M | - | $272.2M |
| QURE | $20.17M | +28.0% | -$232.90M | -1154.8% | $1.72B |
| SRPT | $1.96B | -18.9% | -$114.62M | -5.9% | $1.79B |
| SLDB | - | - | -$215.27M | - | $848.2M |
| RGNX | $153.91M | -4.6% | -$175.23M | -113.9% | $560.1M |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.60B |
| MGTX | $397.50M | +948.3% | $78.98M | 19.9% | $929.7M |
GNPX FAQ
4 questionsIs GNPX profitable?
No. Genprex Inc. reported a net loss of $16.50M for the twelve months ended Jun 30, 2026.How much cash and debt does GNPX have?
Genprex Inc. reported $15.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did GNPX last report financial results?
The latest statements here come from Genprex Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this GNPX financial data come from?
Quantisnow builds these statements from the structured XBRL data Genprex Inc. files with the SEC. It is provided for information only and is not investment advice.